Background-Endovenous recanalization of iliofemoral stenosis or occlusion with angioplasty and stent placement has been increasingly used to maintain long-term venous patency in patients with iliofemoral venous outflow obstruction. The purpose of this systematic review and meta-analysis was to determine safety and effectiveness of venous stent placement in patients with iliofemoral venous outflow obstruction. Methods and Results-We searched MEDLINE and EMBASE for studies evaluating safety or effectiveness of stent placement in patients with iliofemoral venous outflow obstruction. Data were extracted by disease pathogenesis: nonthrombotic, acute thrombotic, or chronic post-thrombotic. Main outcomes included technical success, periprocedural complications, symptom relief at final follow-up, and primary/secondary patency through 5 years. A total of 37 studies reporting 45 treatment effects (nonthrombotic, 8; acute thrombotic, 19; and chronic post-thrombotic, 18) from 2869 patients (nonthrombotic, 1122; acute thrombotic, 629; and chronic post-thrombotic, 1118) were included. Technical success rates were comparable among groups, ranging from 94% to 96%. Complication rates ranged from 0.3% to 1.1% among groups for major bleeding, from 0.2% to 0.9% for pulmonary embolism, from 0.1% to 0.7% for periprocedural mortality, and from 1.0% to 6.8% for early thrombosis. Patient symptom relief data were reported inconsistently. At 1 year, primary and secondary patency were 96% and 99% for nonthrombotic, 87% and 89% for acute thrombotic, and 79% and 94% for chronic post-thrombotic. 
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liofemoral venous obstruction is a common condition that has been implicated as a causal factor in patients with both post-thrombotic syndrome and nonthrombotic chronic venous insufficiency. [1] [2] [3] [4] Venous obstruction can occur as a result of different causes, including extrinsic compression because of malignancy or anatomic variants (eg, May-Thurner syndrome) and acute or chronic deep venous thrombosis (DVT). Patient symptoms are variable and largely dependent on the cause, extent of venous obstruction, and disease duration. Patients with acute DVT often present with sudden onset of lower extremity pain and swelling, whereas those with postthrombotic or long-standing compressive syndromes commonly report chronic pain, edema, and, in advanced cases, ulceration.
The initial treatment for symptomatic acute DVT involves anticoagulation; however, between 23% and 60% of such patients experience post-thrombotic syndrome despite optimal anticoagulant therapy. [5] [6] [7] Chronic post-thrombotic (CPT) syndrome remains a therapeutic challenge, but a strategy of clot removal and restoration of venous outflow has shown promise in reducing its risk. 8 Endovenous treatment of iliofemoral stenosis or occlusion with angioplasty and stent placement has emerged as the procedure of choice to establish and maintain venous outflow. There is considerable variability among studies on the acute and long-term outcomes of iliofemoral venous stent placement, which complicates accurate assessment of these outcomes across different disease pathogenesis. Therefore, we performed a systematic review and meta-analysis on the safety and effectiveness of venous stent placement in patients with nonthrombotic, acute thrombotic (AT), and CPT disease pathogenesis. Given the recent development of stents specifically manufactured for placement in the venous system, a secondary goal of this study was to propose performance goals (PGs) that may be used as comparators in single-arm clinical trials of iliofemoral venous stents.
Study Selection
Two researchers independently selected studies for inclusion in the review. Disagreements were resolved by consensus. Titles and abstracts were initially screened to exclude review articles, commentaries, letters, case reports, and obviously irrelevant studies. Full texts of the remaining articles were retrieved and reviewed. Main inclusion criteria included studies with (1) primary diagnosis of obstructive lesions of the common femoral vein, external iliac vein, and the common iliac vein, (2) stent placement in the common femoral vein, external iliac vein, common iliac vein, and the inferior vena cava, (3) outcomes reported by acute/subacute (<30 days) or chronic (≥30 days; AT and CPT groups only), (4) sample size ≥10, and (5) at least 1 extractable safety or effectiveness outcome. Studies were excluded if they were published in non-English language journals; data were available only from abstracts, conference proceedings, Websites, or personal communication; most treated patients were diagnosed with malignant tumor or inferior vena cava lesion; or most patients received bilateral stents. When multiple studies included overlapping series of patients (ie, kin relationships), only the study with the largest sample size was included.
Data Extraction
An initial database was developed, pilot tested, and refined to maintain consistency with outcomes reported in the literature. Data were extracted from eligible peer-reviewed articles by one author and verified by another author. Data extraction discrepancies between the 2 researchers were resolved by consensus. The types of data recorded in the standardized data extraction forms included general manuscript information, patient characteristics, study characteristics, procedural details, perioperative complications, patient symptom resolution, and primary/ secondary patency. For studies where stent placement was attempted in a subset of patients (eg, >50% stenosis after angioplasty), only data specifically pertaining to patients receiving a stent were extracted.
Definitions and Outcomes
Main outcomes of this study included technical success, periprocedural complications (major bleeding, pulmonary embolism, death, and early thrombosis), patient symptom resolution (ie, pain, edema, and ulcer) at final follow-up, and primary and secondary patency through 5 years. When main outcomes were not explicitly reported, we used the following definitions to attempt extraction of relevant data. Technical success was defined as successful recanalization and stent deployment restoring patency to the target vessel with no major procedural complications. Major bleeding was defined as procedural/ periprocedural access site bleeding requiring transfusion or intervention within 30 days of stent placement. Thirty-day all-cause mortality and pulmonary embolism regardless of severity were recorded. Early thrombosis was defined as restenosis or occlusion of the target lesion within 30 days of the procedure. Patient symptom resolution was determined by the proportion of patients with complete resolution of pain, edema, and ulcer, respectively, at the final follow-up. Partial symptom improvement was considered a failure for analysis purposes. Patency was defined as uninterrupted venous patency (<50% diameter stenosis) without (primary) or with (secondary) a procedure or intervention directly performed on the target lesion. Patency data were extracted from text, life tables, or survival curves at annual intervals through 5 years. Many additional outcomes (eg, stented length, primary assisted patency, change in Clinical-EtiologyAnatomy-Pathophysiology class, change in Villalta scores, and change in quality of life) were initially considered for inclusion, but were discarded after pilot testing because of lack of available data.
Data Analysis
For patient-, study-, and procedure-related data, continuous variables are reported as mean or median, and categorical variables are reported as counts and percentages. Denominators were adjusted when appropriate to include the number of patients, limbs, or procedures. Kaplan-Meier survival estimates were converted to proportions using the number enrolled, number at risk, follow-up distribution when number at risk was not reported, and the survival estimate at the respective time point. Data were extracted by disease pathogenesis: nonthrombotic, AT, or CPT. For each outcome, the pooled estimate and 95% confidence interval (CI) were calculated using a random-effects model given the a priori assumption that treatment effects among studies were heterogeneous. None of the analyses were adjusted for covariates. We used the I 2 statistic to estimate heterogeneity of treatment effects across studies with values of ≤25%, 50%, and ≥ 75% representing low, moderate, and high inconsistency, respectively. 10 Publication bias was visually assessed with funnel plots (not shown) and quantitatively assessed using the Egger regression test. 11 Subgroup analyses were undertaken to explore potential sources of heterogeneity in 1-year primary patency outcomes. P values were 2 sided with a significance level <0.05. All analyses were performed using Comprehensive Meta-analysis (version 2.2; Biostat, Englewood, NJ).
WHAT IS KNOWN
• With the emerging evidence in favor of catheterbased therapies for acute and chronic iliofemoral venous thrombosis, applications of venous stents are expected to grow.
• There are no robust clinical studies documenting long-term outcomes of stent placement for iliofemoral venous obstructions.
WHAT THE STUDY ADDS
• This is the first meta-analysis of stent placement for the treatment of iliofemoral venous outflow obstruction.
• Unlike many studies of iliofemoral venous stent placement, short-and long-term patient outcomes are reported herein according to cause, ie, iliac vein compression syndrome, acute deep vein thrombosis, and chronic post-thrombotic occlusion. 
Results
Study Selection
After screening 793 studies for eligibility, 37 studies reporting 45 treatment effects (nonthrombotic, [12] [13] [14] [15] [16] [17] [18] [19] AT, 13, 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and CPT 12, 14, 17, 30, 33, 34, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] ) from 2869 unique patients (nonthrombotic, 1122; AT, 629; and CPT, 1118) were included in the meta-analysis. The most common reasons for study exclusion were lack of relevant stent placement outcomes (19 studies), kin relationships (18 studies), sample size <10 (16 studies), combined outcome reporting in nonthrombotic and thrombotic patients (8 studies), and combined outcome reporting in AT and CPT patients (6 studies). Eight additional studies were excluded because of irrelevant topics, predominance of malignant lesions, and treatment of only inferior vena cava lesions. A flow diagram of study identification and selection is shown in Figure 1 .
Patient Characteristics
Baseline patient characteristics among the nonthrombotic, AT, and CPT groups are presented in Table 1 . In each group, most patients were women and presented with left limb symptoms. Most patients with thrombotic disease were also diagnosed with iliac vein compression syndrome. Patient characteristics were incompletely described in most studies and hence the denominators for each outcome were variable.
Study Characteristics
Most studies included in this meta-analysis were retrospective (nonthrombotic, 75%; AT, 84%; and CPT, 83%) and conducted at a single institution (nonthrombotic, 88%; AT, 79%; CPT, 89%). Median sample size in each included study was 38 (min-max, 11-518) for nonthrombotic, 26 (min-max, 10-104) for AT, and 33 (min-max, 10-464) for CPT. Median follow-up duration was 19 (min-max, 10-50) months for nonthrombotic, 17 (min-max, 6-80) months for AT, and 15 (minmax, 6-46) months for CPT (Table 2) .
Procedural Details
In general, AT was treated with catheter-directed thrombolysis (with or without thrombectomy) and followed by PTA and stent placement. Nonthrombotic and CPT were typically treated with PTA and stent placement although adjunctive therapies were applied in some cases. Wallstents (Boston Scientific, Marlborough, MA) were used in 78% of included studies. Only 1 study (3%) used a stent specifically manufactured for venous applications in 3 (0.1%) limbs. 39 In general, more stents were placed in patients with CPT lesions than in patients with nonthrombotic and AT lesions (Table 3) . Anticoagulation regimens involved an initial bolus of 4000 to 5000 IU intravenous heparin at the start of the procedure and as needed during the procedure to achieve a target activated clotting time of 280 to 300 seconds. After the procedure, low molecular weight heparin was administered until discharge. Thereafter, anticoagulation (most commonly warfarin) for 2 to 6 months with a target international normalized ratio of 2.0 to 3.0 was typical. In patients at high risk for thrombosis, anticoagulation regimens were extended to 6 to 12 months. Lifelong antiplatelet medication was routinely prescribed in some studies.
Technical Success
Technical success rates were comparable among groups, ranging from 94% in AT and CPT to 96% in nonthrombotic patients (Table 4 ). Publication bias was evident for technical success outcomes in AT patients.
Perioperative Complications
Major periprocedural complications were rare in each group (Table 4) . Complication rates ranged from 0.3% to 1.1% among groups for major bleeding, from 0.2% to 0.9% for pulmonary embolism, and from 0.1% to 0.7% for periprocedural mortality. Descriptions of major bleeding included wound hematoma evacuation (2), infected hematoma (1), common 
Symptom Relief
The percentage of patients reporting complete relief of venous symptoms after stent placement was not reported in most studies. Of the nonthrombotic and CPT studies reporting these data, complete symptom relief at the final follow-up visit was reported in 69% to 82% of patients for pain, 64% to 68% of patients for edema, and 71% to 81% of patients for ulcer healing. Symptom relief data were rarely reported in patients with acute DVT. Significant heterogeneity among studies was identified for relief of pain and edema (Table 4) .
Patency
Primary patency was typically evaluated with duplex ultrasonography; however, a formal definition of primary patency was rarely provided, and independent assessment of image quality and findings was not provided (Table II in the Data  Supplement) . Primary patency at 1 year was 96% (95% CI, 93%-98%) for nonthrombotic, 87% (95% CI, 80%-92%) for AT, and 79% (95% CI, 76%-83%) for CPT. Significant heterogeneity and publication bias were observed in the AT group, but not in the nonthrombotic or CPT. Secondary patency at 1 year was 99% (95% CI, 88%-100%) for nonthrombotic, 89% (95% CI, 76%-95%) for AT, and 94% (95% CI, 90%-96%) for CPT. Primary and secondary patency remained higher in nonthrombotic patients versus AT and CPT patients through 5 years (Figures 2 and 3 ).
Subgroup Analyses
We performed predefined subgroup analyses to identify the influence of study-and patient-related characteristics on primary patency at 1 year. Within each patient group, we identified no variable that significantly influenced primary patency rates (Table 5) . However, many studies inadequately reported outcomes and, consequently, comparisons often included too few studies to draw any meaningful conclusions.
Discussion
To our knowledge, this is the first meta-analysis of stent placement for the treatment of iliofemoral venous outflow obstruction. Overall, results of this analysis indicate that stent placement has a high technical success rate and is effective in restoring and maintaining patency in patients with iliofemoral venous outflow obstruction because of iliac vein compression syndrome, acute DVT, or CPT occlusion. The long-term patency of stents seems to be somewhat lower in patients with thrombotic disease than in those with nonthrombotic iliac vein compression although formal statistical testing for group differences was not conducted because of the limited number of available studies. Although the degree of symptom relief was inconsistently reported, majority of patients experienced complete resolution of symptoms after the procedures. In terms of safety profile, venous stent placement is associated with a low complication rate of <1% for bleeding, PE, and mortality. It should be noted that the reported 30-day bleeding rates in the AT group were likely because of CDT and subsequent anticoagulation regimens rather than the stent placement per se as evidenced by the apparent lower bleed rate among nonthrombotic groups than among AT group (0.3% versus 1.1%).
Early thrombosis seems to be related to the cause of the obstructive lesion with the highest thrombosis rate observed in the AT and CPT groups (≤6.5% and 6.8%, respectively). Factors that may impact postprocedural stent thrombosis rate include the quality of inflow and outflow through the stented segment(s), rigor of anticoagulation regimen, lesion length and location, stent diameter and length, and patient characteristics. Unfortunately the quality of the reported data was insufficient to determine the impact of these variables on early stent thrombosis.
An important aspect of the current meta-analysis is that stent placement outcomes were reported separately based on distinct venous disease pathogenesis. Eijgenraam et al 49 performed a systematic review of the effect of antithrombotic therapy with venous stenting after DVT. However, the authors combined data from AT and CPT studies, included data from studies where stents were not placed in all patients, did not include nonthrombotic patients, and did not use meta-analytic techniques to synthesize main outcomes. The practice of reporting outcomes in mixed populations (eg, combining acute and chronic DVT, nonthrombotic and thrombotic causes, or stent and no stent) was frequently identified during the conduct of the current systematic review and served as a common reason for study exclusion. In accordance with reporting standards set forth by the Society of Interventional Radiology, 50 we recommend that future studies explicitly detail patient outcomes, at a minimum, according to the cause and treatment administered. Furthermore, data elements such as stent location, diameter, length, and quality of venous inflow and outflow should also be systematically recorded.
We made no attempt to determine the comparative safety and effectiveness of stent placement versus no stent placement because of a paucity of available literature. In the National Venous Registry, which was a prospective multicenter registry of patients with DVT treated by CDT, a higher venous patency was observed in patients who had stents placed than in those who did not. 29 Similar results were reported by Meng et al 28 who conducted a randomized controlled trial evaluating stent placement in patients with acute DVT. Patients who underwent stent placement resulted in higher 1-year primary patency (86% versus 55%) and superior improvements in clinical (C) class according to the Clinical-EtiologyAnatomy-Pathophysiology (CEAP) classification, Venous Clinical Severity Score, and Chronic Venous Insufficiency Questionnaire scores than those with no stent. On balance, the Primary patency at 1 year is a standard effectiveness end point in clinical trials of endovascular treatment of femoropopliteal arterial lesions and in ongoing studies of iliofemoral venous stents. Given the lack of a commonly accepted comparator for venous stents and because most available studies are small, retrospective, single-site evaluations, the pooled data from this meta-analysis represent the highest quality data available to use for PG development in clinical trials of iliofemoral venous stent placement. The typical approach to developing a PG is to identify the lower or upper 95% confidence limit of the estimate (depending on outcome) and then add or subtract a margin from that value. For safety outcomes, we recommend taking a more conservative approach for identifying a PG for venous stent trials by using the appropriate 95% confidence limit with no additional margin applied. However, because most studies were retrospective with no formal definitions for patency, primary and secondary patency estimates are likely overestimated in comparison with prospective trials with imaging core laboratory patency assessments using objective criteria. Therefore, in the case of primary/secondary patency, we propose subtracting a margin of 5% to 10% from the lower 95% confidence limits identified in this meta-analysis to establish a PG. Specifically, the lower 95% confidence limit of primary patency outcomes at 1 year in a clinical trial of venous stents must exceed the PG to It is important to discuss several inherent limitations considering that the estimates were primarily derived from retrospective case series. In the absence of available patient-level data, development of a PG is constrained by the quantity and quality of peer-reviewed literature. Unreported confounding factors such as patient and procedural characteristics, medical history, disease severity, physician experience, and periprocedural anticoagulant regimens may diminish the interpretability of outcomes. We attempted to extract all possible confounders and perform subgroup analyses to determine their influence on primary patency. Unfortunately, the number of available studies with complete data were inadequate for some comparisons. Despite the known limitations of the current review, the data herein represent the most comprehensive synthesis of data available for iliofemoral venous stent placement and thus a reasonable starting point for PG development. As data from prospective venous stent clinical trials become available, we anticipate that the choice of study end points and outcome comparators will be refined over time.
This meta-analysis is associated with several issues that may influence interpretation. We did not attempt to analyze treatment effects by stent type because these data were not reported. Of the stents deployed in included studies, 99.9% were developed for nonvenous applications; stents manufactured specifically to accommodate venous anatomy are currently in clinical trials because there is no on-label stent approved specifically for this indication in the United States. The rationale for stent placement (routine versus ≥50% residual thrombus after angioplasty) was inadequately described in most studies and was further confounded because many retrospective studies included only patients treated with a stent. There was significant variability in the consistency and thoroughness of patient characteristics and outcomes reporting among studies. Finally, this meta-analysis was composed primarily of retrospective, single-site, level IV studies. Strengths of this meta-analysis are structured data extraction methodology, exclusion of multiple publications reporting on common patients, outcomes reporting by distinct venous disease pathogenesis, and inclusion of all relevant studies, including those where only a subset of patients underwent attempted stent placement provided stent-specific outcomes were reported.
Conclusions
Stent placement for iliofemoral venous obstruction results in high technical success and low complication rates regardless of disease pathogenesis. Avoidance of early thrombosis and maintenance of long-term patency remain therapeutic challenges with stent placement in patients with acute DVT and CPT syndrome. We propose a mechanism for PG comparisons so that future trials of stents designed specifically for this indication may be implemented.
